FDA releases hold on second of Intellia’s ATTR-CM gene therapy trials

Intellia is now able to continue both Phase III trials of nex-z. Credit: Piotr Swat / Shutterstock.com (Piotr Swat / Shutterstock.com) The US Food and Drug Administration (FDA) has released the ...
The American Journal of Managed Care

Key Efficacy and Safety Considerations for Payers in ATTR-CM

Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety.
The American Journal of Managed Care

Evaluating Transthyretin Stabilizers and Silencers in ATTR-CM

In ‘Evaluating Transthyretin Stabilizers and Silencers in ATTR-CM,’ our panel delves into the segment by asking Dr. Alexander to explain the differences between transthyretin ...